Key facts
- Araceli Biosciences’s last known valuation is $27.0M (Nov 2025).
- It has raised $14.5M across 2 recorded rounds; the latest was Early Stage VC ($12.2M) in Dec 2024.
- Notable investors include Fluke Venture Partners, William Cortelyou.
- Araceli Biosciences has filed 3 Form Ds with the SEC since 2023, most recently Dec 2025 ($12.2M sold to 28 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Araceli Biosciences
Funding rounds
2 roundsAbout Araceli Biosciences
Developer of advanced imaging technologies intended to enhance the drug discovery process for researchers. The company's technologies offer features such as predictive AI-based image acquisition and analysis, rapid scanning capabilities that reduce the time for screening compounds, and hardware, enabling pharmaceutical and biotech companies to streamline their research efforts while providing an efficient path to therapeutic development and improved patient outcomes.
- Sector
- Healthcare
- HQ
- Tigard, OR, United States
- Founded
- 2020
- Employees
- 45
- Website
- aracelibio.com/
- Ownership
- Privately Held (backing)
Araceli Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Araceli Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Araceli Biosciences in its N-PORT filings yet. We sweep new filings monthly.